The fear of radiotherapy-induced urinary incontinence (URINC) often contraindicates postprostatectomy RT (POPRT), despite the lack of accurate data about its real incidence and severity. The purpose of this analysis was to analyze clinico-dosimetric factors predicting severe, self-reported URINC 1 and 2 years after POPRT.
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Purpose or Objective: In the present study, conventionally fractionationed volumetric arc therapy (VMAT) and hypofractionated stereotactic body radiotherapy (SBRT) modalities were aimed to compare in terms of side effects and quality of life (QOL) in patients with localized prostate cancer.
Material and Methods:
Patients who admitted to I.U. Institute of Oncology with a diagnosis of localized prostate cancer during the period from March 2010 to December 2013 were included into the study. Patients received radical RT with dose schedules of either 33.5 Gy/5 fr for SBRT or 75.6 Gy/35 fr for VMAT. Acute and late side effects of treatment were evaluated according to CTCAE version 4. IPSS and EORTC QOL-PR25 forms were used to assess QOL at baseline, end of treatment and during follow-up.
Results:
Of the 48 patients (28 SBRT, 20 VMAT) who were included into the study, 40 (20 SBRT, 20 VMAT) were evaluated for their QOL status. All demographic and pathological features including median age of the patients, clinical manifestations, and the risk groups were found to be similar between treatment groups. PSA control rates were %100 in both arms during the follow up with a median of 23 months. PSA nadir values were detected to be 0.5 ng/dl in both arms. PSA bounce was observed in 43% and 50% of patients in SBRT and VMAT arms, respectively. The magnitude of PSA bounce value was significantly higher in SBRT arm compared with VMAT (0.8 ng/dl vs. 0.1 ng/dl, p= 0.01). PSA decline rate in VMAT arm was found to be significantly higher than in SBRT arm (p = 0.028). Grade 3 rectal toxicity was not observed in any of the treatment arms. Although Grade 3 urinary side effects were not seen in patients treated with VMAT technique, 3 patients (10.7%) in SBRT arm with a history of TURP before RT experienced Grade 3 urinary toxicity. No significant difference was observed between the two arms concerning sexual activity functioning and sexual functioning scores whereas the scores at 10.5 and 13.5 months were found to be significantly decrased compared with baseline in both treatment arms. SBRT and VMAT arms did not differ significantly regarding urinary, incontinence, bowel symptom scores and IPSS obstruction scores. The magnitude of increase in IPSS scores at the end of the treatment compared with baseline were detected to be significantly higher in VMAT arm than SBRT arm (p=0.046). The decrease in hormonal symptom scores at 4.5, 10.5 and 13.5 months compared with baseline was detected to be significantly higher in VMAT arm than SBRT arm (p=0.007, p=0.027, and p=0.021, respectively).
Conclusion:
Both SBRT and VMAT treatments were highly successful in terms of PSA control. QOL assessment were found to be mostly similar between treatment modalities. Grade 3 urinary toxicities might be eliminated with careful patient selection for SBRT technique Purpose or Objective: The aim of this work is to develop an algorithm to predict recurrence in prostate cancer patients treated with radical radiotherapy, getting up to a prognostic power higher than traditional D'Amico risk classification.
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Material and Methods: 2493 men belonging to the EUREKA-2 retrospective multi-centric database on prostate cancer and treated with external-beam radiotherapy (3D-CRT and or IMRT) as primary treatment comprised the study population. A Cox regression time to PSA failure analysis was performed in univariate and multivariate settings, evaluating the predictive ability of age, pre-treatment PSA, clinicalradiological staging, Gleason score and percentage of positive cores at biopsy (%PC). The accuracy of this model was checked with bootstrapping statistics. Subgroups for all the variables' combinations were combined to classify patients into five different "Candiolo" risk-classes for biochemical Progression Free Survival (bPFS); thereafter, they were also applied to clinical PFS (cPFS), systemic PFS (sPFS) and Prostate Cancer Specific Survival (PCSS), and compared to D'Amico risk grouping performances.
Results: the Candiolo classifier splits patients in 5 risk-groups with the following 10-years bPFS, cPFS, sPFS and PCSS: for very-low-risk 90%, 94%, 100% and 100%; for low-risk 74%, 88%, 94% and 98%; for intermediate-risk 60%, 82%, 91% and 92%; for high-risk 43%, 55%, 80% and 89% and for very-high-risk 14%, 38%, 56% and 70%. Our classifier outperforms D'Amico risk classes for all the end-points evaluated, with concordance indexes of 71.5%, 75.5%, 80% and 80.5% versus 63%, 65.5%, 69.5% and 69%, respectively. 
Conclusion

